Home › Hidradenitis Suppurativa › Louisiana › New Orleans
Hidradenitis Suppurativa clinical trials in New Orleans, LA
4 studies for Hidradenitis Suppurativa are looking for participants at sites in and around New Orleans (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Oruka Therapeutics Investigative Site, New Orleans
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
- Investigative Site US057, New Orleans
Myriad™ Augmented Soft Tissue Reconstruction Registry
RecruitingObservational study
- University Medical Center, New Orleans
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RecruitingPhase 2
- Lakeside Hospital, New Orleans
- LCMC Multi-speciality Clinic, New Orleans
- University Medical Center, New Orleans
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
More about Hidradenitis Suppurativa on MedlinePlus
Hidradenitis Suppurativa trials in other cities
- Boston, MA9 studies
- Tampa, FL7 studies
- Miami, FL6 studies
- New York City, NY5 studies
- Birmingham, AL5 studies
- Dallas, TX5 studies
- Phoenix, AZ5 studies
- Santa Clarita, CA4 studies
- Scottsdale, AZ4 studies
- Durham, NC4 studies
- Minneapolis, MN4 studies
- Philadelphia, PA4 studies
Other studies in New Orleans
- Cancer (all types)12 studies
- Ovarian Cancer12 studies
- Breast Cancer11 studies
- Prostate Cancer10 studies
- Endometrial Cancer9 studies
- Metastatic Cancer9 studies
- Lung Cancer9 studies
- Non-Small Cell Lung Cancer9 studies
- Cardiovascular Disease9 studies
- Obesity8 studies
- Steatotic Liver Disease8 studies
- Colorectal Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.